Novo Nordisk Partners with Anthropic AI for Drug Development
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
Novo Nordisk Partners with Anthropic AI for Drug Development
- Novo Nordisk is collaborating with Anthropic to accelerate drug discovery and development, a move aimed at enhancing productivity in research and development and shortening the time from research to market.
- Mike Doustdar, President and CEO of Novo Nordisk, stated on Wednesday, September 16, 2026, that this partnership reflects the company's ambition to become the "world's most AI-driven healthcare company."
Full Summary — powered by AI
Novo Nordisk and Anthropic PBC announced on Wednesday, September 16, 2026, a partnership to integrate artificial intelligence into drug development processes. The collaboration seeks to accelerate the discovery and development of new medicines, a critical objective as Novo Nordisk intensifies its efforts in the competitive obesity market.
The Danish pharmaceutical company plans to initially implement Anthropic’s Claude Science for specific research and development workflows. This will focus on scientific challenges where the combined expertise of both companies is expected to yield the most significant impact. Mike Doustdar, President and CEO of Novo Nordisk, emphasized that AI can boost R&D productivity and compress the timeline from initial research to product launch. Dario Amodei, co-founder and CEO of Anthropic, highlighted the potential for AI to compress a century’s worth of biological and medical breakthroughs into a single decade.
This partnership is part of Novo Nordisk’s broader strategy to leverage AI. Earlier this year, the company also formed a strategic alliance with OpenAI to apply AI across various operations, including drug discovery, manufacturing, and commercial activities, with full integration expected by late 2026. Additionally, Novo Nordisk has established an AI innovation hub with Amazon Web Services. The company has previously used AI to streamline the creation of clinical study reports, reducing a process that once took 15 weeks for a team of 40-50 people to just minutes for three individuals, cutting the time to generate critical documentation by over 90 percent.
Anthropic has also been expanding its presence in the healthcare sector, having previously partnered with Bristol-Myers Squibb to provide access to Claude for research and drug development. In February 2026, Anthropic announced partnerships with the Allen Institute and Howard Hughes Medical Institute to build specialized AI agents for biomedical research. The company also signed the Centers for Medicare & Medicaid Services (CMS) Health Tech Ecosystem pledge in July 2025 to advance healthcare interoperability.